Crinetics Pharmaceuticals Inc (CRNX)

$42.23 +3.55 (9.18%)
Market Cap 4.45B
Revenue (ttm) 7.70M
Net Income (ttm) -465.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,043.12%
Debt to Equity Ratio 0.00
Volume 2,176,700
Avg Vol 1,287,958
Day's Range N/A - N/A
Shares Out 105.44M
Stochastic %K 98%
Beta 0.23
Analysts Strong Sell
Price Target $83.14

Company Profile

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant,...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 450 6464
Address:
6055 Lusk Boulevard, San Diego, United States
topstockalerts
topstockalerts Jul. 3 at 10:48 PM
$CRNX this looks like it wants higher honestly
1 · Reply
IN0V8
IN0V8 Jul. 2 at 6:13 PM
$CRNX Opportunity UBS initiates coverage with buy rating; PT $55
0 · Reply
CDMO
CDMO Jul. 2 at 1:52 PM
$CRNX told ya! Why though? Because of some analyst bs?
1 · Reply
GrowthVision
GrowthVision Jul. 2 at 1:21 PM
$CRNX UBS initiated coverage with a Buy and $55 PT. Bullish read from the street, but the market still needs to confirm. If momentum builds, this can stay in play.
0 · Reply
Quantumup
Quantumup Jul. 2 at 12:34 PM
UBS🏁 $CRNX Buy-$55 and said: We believe that YTD stock pullback (-44% from mid-Jan) provides an attractive entry point for multiple catalysts from potentially best-in-disease pipeline drugs with high likelihood of success. AZN $CORT $NBIX XERS NVS IPSEY RICFY Here's what else UBS had to say in its initiation report: https://x.com/Quantumup1/status/2072659812567941348?s=20
0 · Reply
CH_Expat
CH_Expat Jul. 2 at 5:46 AM
$MLYS $CRNX $TARS $IDYA I was finally able to open positions in all stocks I wanted for averages I can live with. All of those were not part of the XBI-Surge.
0 · Reply
CDMO
CDMO Jul. 1 at 2:34 PM
$CRNX back to >40
0 · Reply
NT72
NT72 Jul. 1 at 12:27 PM
$CRNX still a massive disconnect between price and value. Hopefully, we get our run soon. They must be excited about Q2 numbers to announce so quickly!
0 · Reply
DeepSeaTurtle
DeepSeaTurtle Jun. 30 at 2:05 PM
$LLY basically just showed the next wave of obesity biotech winners. 5 names I’m watching for 10x potential: $VKTX $ALT $CRNX $RYTM ARGX Momentum is shifting. Don’t ignore this rotation.
1 · Reply
CH_Expat
CH_Expat Jun. 29 at 6:56 PM
$CRNX Added. Fake fckry here. Tell me what you want, something is on here. Brutal no news move to 50s in one month or BO. XBI-Underperformance becomes more and more absurd.
1 · Reply
Latest News on CRNX
Crinetics initiated with a Buy at UBS

2026-07-02T08:40:07.000Z - 2 days ago

Crinetics initiated with a Buy at UBS

Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

Jun 30, 2026, 4:05 PM EDT - 4 days ago

Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

Crinetics Pharmaceuticals Transcript: AGM 2026

Jun 18, 2026, 11:00 AM EDT - 16 days ago

Crinetics Pharmaceuticals Transcript: AGM 2026

Crinetics presents full results from Phase 2 trial of atumelnant

2026-06-14T21:00:05.000Z - 20 days ago

Crinetics presents full results from Phase 2 trial of atumelnant

Crinetics presents long-term data from program evaluating Palsonify

2026-06-14T20:55:05.000Z - 20 days ago

Crinetics presents long-term data from program evaluating Palsonify

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Jun 14, 2026, 2:45 PM EDT - 20 days ago

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Leerink sees favorable readthrough to Crinetics after Camurus’ Oclaiz CRL

2026-06-11T15:05:53.000Z - 23 days ago

Leerink sees favorable readthrough to Crinetics after Camurus’ Oclaiz CRL

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy' Initiative to Empower People Across Endocrine Disease Communities

Jun 2, 2026, 4:05 PM EDT - 4 weeks ago

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy' Initiative to Empower People Across Endocrine Disease Communities

Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

Jun 2, 2026, 4:55 AM EDT - 4 weeks ago

Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

May 22, 2026, 4:05 PM EDT - 6 weeks ago

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

Crinetics price target lowered to $88 from $89 at Evercore ISI

2026-05-15T12:39:52.000Z - 7 weeks ago

Crinetics price target lowered to $88 from $89 at Evercore ISI

Crinetics price target lowered to $84 from $87 at Oppenheimer

2026-05-11T17:08:57.000Z - 7 weeks ago

Crinetics price target lowered to $84 from $87 at Oppenheimer

Crinetics price target lowered to $95 from $97 at Citizens

2026-05-08T09:55:10.000Z - 2 months ago

Crinetics price target lowered to $95 from $97 at Citizens

Crinetics Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Crinetics Pharmaceuticals Earnings Call Transcript: Q1 2026

Crinetics Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Crinetics Pharmaceuticals Earnings release: Q1 2026

Crinetics Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Crinetics Pharmaceuticals Quarterly report: Q1 2026

Crinetics Pharmaceuticals Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Crinetics Pharmaceuticals Slides: Q1 2026

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026, 4:05 PM EDT - 2 months ago

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Crinetics Pharmaceuticals Proxy statement: Proxy filing

Crinetics Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Crinetics Pharmaceuticals Proxy statement: Proxy filing

Crinetics price target raised to $97 from $96 at Citizens

2026-04-28T09:45:54.000Z - 2 months ago

Crinetics price target raised to $97 from $96 at Citizens

Crinetics’ Palsonify approved by European Commission for acromegaly

2026-04-27T21:22:32.000Z - 2 months ago

Crinetics’ Palsonify approved by European Commission for acromegaly

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Apr 27, 2026, 5:13 PM EDT - 2 months ago

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Apr 8, 2026, 4:05 PM EDT - 3 months ago

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Crinetics submits Palsonify marketing authorization application to ANVISA

2026-03-26T20:40:14.000Z - 3 months ago

Crinetics submits Palsonify marketing authorization application to ANVISA

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Mar 26, 2026, 4:05 PM EDT - 3 months ago

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Crinetics Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 1:50 PM EST - 4 months ago

Crinetics Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Crinetics Pharmaceuticals Slides: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 1:50 PM EST - 4 months ago

Crinetics Pharmaceuticals Slides: TD Cowen 46th Annual Health Care Conference

Crinetics price target lowered to $96 from $105 at Citizens

2026-03-02T10:53:36.000Z - 4 months ago

Crinetics price target lowered to $96 from $105 at Citizens

Crinetics price target lowered to $83 from $84 at Stifel

2026-02-27T12:45:42.000Z - 4 months ago

Crinetics price target lowered to $83 from $84 at Stifel

Crinetics reports Q4 EPS ($1.29), consensus ($1.37)

2026-02-26T22:07:45.000Z - 4 months ago

Crinetics reports Q4 EPS ($1.29), consensus ($1.37)

Crinetics Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Crinetics Pharmaceuticals Earnings Call Transcript: Q4 2025

Crinetics Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Crinetics Pharmaceuticals Annual report: Q4 2025

Crinetics Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Crinetics Pharmaceuticals Earnings release: Q4 2025

Crinetics Pharmaceuticals Slides: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Crinetics Pharmaceuticals Slides: Q4 2025

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 4:05 PM EST - 4 months ago

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

Feb 5, 2026, 4:05 PM EST - 5 months ago

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

Crinetics price target raised to $84 from $75 at Stifel

2026-01-30T12:36:13.000Z - 5 months ago

Crinetics price target raised to $84 from $75 at Stifel

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Jan 26, 2026, 5:00 PM EST - 5 months ago

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Crinetics doses first patient in BALANCE-CAH trial

2026-01-22T21:25:50.000Z - 5 months ago

Crinetics doses first patient in BALANCE-CAH trial

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Jan 22, 2026, 4:05 PM EST - 5 months ago

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 12:45 PM EST - 6 months ago

Crinetics Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Crinetics Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 12:45 PM EST - 6 months ago

Crinetics Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2026, 4:05 PM EST - 6 months ago

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Jan 6, 2026, 9:22 PM EST - 6 months ago

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Jan 5, 2026, 4:02 PM EST - 6 months ago

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Crinetics Pharmaceuticals Transcript: Study Update

Jan 5, 2026, 8:30 AM EST - 6 months ago

Crinetics Pharmaceuticals Transcript: Study Update

Crinetics Pharmaceuticals Press release: Study Update

Jan 5, 2026, 8:30 AM EST - 6 months ago

Crinetics Pharmaceuticals Press release: Study Update

Crinetics Pharmaceuticals Slides: Study Update

Jan 5, 2026, 8:30 AM EST - 6 months ago

Crinetics Pharmaceuticals Slides: Study Update

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Jan 5, 2026, 8:00 AM EST - 6 months ago

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

Jan 4, 2026, 4:00 PM EST - 6 months ago

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 4:05 PM EST - 7 months ago

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Dec 11, 2025, 4:05 PM EST - 7 months ago

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2025, 4:34 PM EST - 7 months ago

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Dec 3, 2025, 8:00 AM EST - 7 months ago

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

Nov 20, 2025, 4:05 PM EST - 8 months ago

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 4:28 PM EST - 8 months ago

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Crinetics Pharmaceuticals Earnings Call Transcript: Q3 2025

Crinetics Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Crinetics Pharmaceuticals Quarterly report: Q3 2025

Crinetics Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Crinetics Pharmaceuticals Earnings release: Q3 2025

Crinetics Pharmaceuticals Slides: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Crinetics Pharmaceuticals Slides: Q3 2025

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 8 months ago

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

Oct 23, 2025, 8:00 AM EDT - 9 months ago

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 10, 2025, 4:41 PM EDT - 9 months ago

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 6, 2025, 4:05 PM EDT - 9 months ago

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Crinetics Pharmaceuticals Transcript: FDA Announcement

Sep 25, 2025, 6:00 PM EDT - 10 months ago

Crinetics Pharmaceuticals Transcript: FDA Announcement

Crinetics Pharmaceuticals Press release: FDA Announcement

Sep 25, 2025, 6:00 PM EDT - 10 months ago

Crinetics Pharmaceuticals Press release: FDA Announcement

Crinetics Pharmaceuticals Slides: FDA Announcement

Sep 25, 2025, 6:00 PM EDT - 10 months ago

Crinetics Pharmaceuticals Slides: FDA Announcement

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Sep 25, 2025, 5:30 PM EDT - 10 months ago

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 10, 2025, 4:30 PM EDT - 10 months ago

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

Aug 21, 2025, 8:45 AM EDT - 11 months ago

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 11, 2025, 4:05 PM EDT - 11 months ago

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Crinetics Pharmaceuticals Earnings Call Transcript: Q2 2025

Crinetics Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Crinetics Pharmaceuticals Quarterly report: Q2 2025

Crinetics Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Crinetics Pharmaceuticals Earnings release: Q2 2025

Crinetics Pharmaceuticals Slides: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Crinetics Pharmaceuticals Slides: Q2 2025

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 4:05 PM EDT - 11 months ago

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Jul 13, 2025, 5:45 PM EDT - 1 year ago

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 10, 2025, 4:28 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

Jun 30, 2025, 4:05 PM EDT - 1 year ago

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

Crinetics Pharmaceuticals Transcript: R&D Day 2025

Jun 26, 2025, 9:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals Transcript: R&D Day 2025

Crinetics Pharmaceuticals Slides: FY 2025

Jun 26, 2025, 9:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals Slides: FY 2025

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 10, 2025, 4:29 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 12:50 PM EDT - 1 year ago

Crinetics Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Crinetics Pharmaceuticals Slides: Corporate Presentation

Jun 3, 2025, 4:00 PM EDT - 1 year ago

Crinetics Pharmaceuticals Slides: Corporate Presentation

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

May 23, 2025, 8:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

Crinetics Pharmaceuticals Proxy statement: Proxy Filing

May 20, 2025, 8:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals Proxy statement: Proxy Filing

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

May 15, 2025, 4:05 PM EDT - 1 year ago

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 12, 2025, 4:05 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Crinetics Pharmaceuticals Earnings Call Transcript: Q1 2025

Crinetics Pharmaceuticals Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Crinetics Pharmaceuticals Quarterly report: Q1 2025

Crinetics Pharmaceuticals Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Crinetics Pharmaceuticals Earnings release: Q1 2025

Crinetics Pharmaceuticals Slides: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Crinetics Pharmaceuticals Slides: Q1 2025

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals Proxy statement: Proxy Filing

Crinetics Pharmaceuticals Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals Proxy statement: Proxy Filing

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 10, 2025, 5:04 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 10, 2025, 4:36 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 4:20 PM EDT - 1 year ago

Crinetics Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2025

Crinetics Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 11:10 AM EST - 1 year ago

Crinetics Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Crinetics Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Crinetics Pharmaceuticals Earnings Call Transcript: Q4 2024

Crinetics Pharmaceuticals Annual report: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Crinetics Pharmaceuticals Annual report: Q4 2024

Crinetics Pharmaceuticals Earnings release: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Crinetics Pharmaceuticals Earnings release: Q4 2024

Crinetics Pharmaceuticals Slides: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Crinetics Pharmaceuticals Slides: Q4 2024

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 4:05 PM EST - 1 year ago

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

Feb 24, 2025, 8:30 AM EST - 1 year ago

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

Feb 20, 2025, 4:05 PM EST - 1 year ago

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

topstockalerts
topstockalerts Jul. 3 at 10:48 PM
$CRNX this looks like it wants higher honestly
1 · Reply
IN0V8
IN0V8 Jul. 2 at 6:13 PM
$CRNX Opportunity UBS initiates coverage with buy rating; PT $55
0 · Reply
CDMO
CDMO Jul. 2 at 1:52 PM
$CRNX told ya! Why though? Because of some analyst bs?
1 · Reply
GrowthVision
GrowthVision Jul. 2 at 1:21 PM
$CRNX UBS initiated coverage with a Buy and $55 PT. Bullish read from the street, but the market still needs to confirm. If momentum builds, this can stay in play.
0 · Reply
Quantumup
Quantumup Jul. 2 at 12:34 PM
UBS🏁 $CRNX Buy-$55 and said: We believe that YTD stock pullback (-44% from mid-Jan) provides an attractive entry point for multiple catalysts from potentially best-in-disease pipeline drugs with high likelihood of success. AZN $CORT $NBIX XERS NVS IPSEY RICFY Here's what else UBS had to say in its initiation report: https://x.com/Quantumup1/status/2072659812567941348?s=20
0 · Reply
CH_Expat
CH_Expat Jul. 2 at 5:46 AM
$MLYS $CRNX $TARS $IDYA I was finally able to open positions in all stocks I wanted for averages I can live with. All of those were not part of the XBI-Surge.
0 · Reply
CDMO
CDMO Jul. 1 at 2:34 PM
$CRNX back to >40
0 · Reply
NT72
NT72 Jul. 1 at 12:27 PM
$CRNX still a massive disconnect between price and value. Hopefully, we get our run soon. They must be excited about Q2 numbers to announce so quickly!
0 · Reply
DeepSeaTurtle
DeepSeaTurtle Jun. 30 at 2:05 PM
$LLY basically just showed the next wave of obesity biotech winners. 5 names I’m watching for 10x potential: $VKTX $ALT $CRNX $RYTM ARGX Momentum is shifting. Don’t ignore this rotation.
1 · Reply
CH_Expat
CH_Expat Jun. 29 at 6:56 PM
$CRNX Added. Fake fckry here. Tell me what you want, something is on here. Brutal no news move to 50s in one month or BO. XBI-Underperformance becomes more and more absurd.
1 · Reply
NT72
NT72 Jun. 26 at 5:10 PM
$CRNX Anyone know what's up with the volume today? Volume before price as they say... one of the few attractive Bios that hasn't run yet. Interesting analysis on X: https://x.com/BreachHorizon/status/2070524991251333345
1 · Reply
CH_Expat
CH_Expat Jun. 25 at 6:50 PM
$CRNX Keep in mind they want to make the 30s your fake anchor. This is worthy way more and it was trading in the 50s. PALSONIFY alone will make 1.5b peak sales in Acromegaly. Atumelant is much better than Cressenity and Cressenity sells very good. Cushing will hit as well, NET is underestimated. Are you smarter than the Baker Bros? I am not. But my average is better than theirs and so can be yours. Cc @DLAT94
0 · Reply
CH_Expat
CH_Expat Jun. 24 at 4:01 PM
$CRNX Not a lot of undervaluations in quality bioland. Here we have one.
1 · Reply
heyupikachu1821
heyupikachu1821 Jun. 22 at 9:29 PM
$CRNX I’d like to see momentum return to this stock. I’ve done a couple of really decent swing trades with Crinetics. the current levels feel like a longterm value buy (imo). back in and hoping to ride to wave to the 80’s at least
0 · Reply
Quantumup
Quantumup Jun. 22 at 7:47 PM
Stifel reiterated $CRNX Buy; $83 after a chat w/ MGMT.. $AZN NBIX $CORT XERS NVS IPSEY RICFY Here's what Stifel said in its note: https://x.com/Quantumup1/status/2069145144683565107?s=20
0 · Reply
CH_Expat
CH_Expat Jun. 22 at 5:59 PM
$CRNX Proud No. 74 out of 75 on my biowatchlist while overvalued stuff like SYRE is exploding. Fake.
0 · Reply
CH_Expat
CH_Expat Jun. 17 at 4:00 PM
$IDYA $CRNX XBI up 1% = we are red XBI flat = we are red 2% XBI down 2% = we are down 4% XBI going through the roof = we are up 3%
0 · Reply
CH_Expat
CH_Expat Jun. 17 at 11:58 AM
$CRNX 40% underperformance of XBI YTD. Yes, the same XBI which is full of ovevalued shitty bios.
0 · Reply
Quantumup
Quantumup Jun. 16 at 6:01 PM
Citizens reiterated $CRNX Market Outperform; $95 and assigned atumelnant a 70% POS in CAH and 50% in Cushing's, w/ combined peak sales pot'l of $1.5B after CRNX's presentation at ENDO2026. $BBIO NBIX $NVS RICFY PFE IPSEY AZN Here's what Citizens said: https://x.com/Quantumup1/status/2066943674911424639?s=20
0 · Reply
CH_Expat
CH_Expat Jun. 16 at 6:01 PM
$IDYA unchanged, $CRNX I added after strong ENDO-Updates, opened a position at $MLYS, waiting for $TARS to go a bit more southwards. Hard to find value in quality these days. Ready to add CRNX and MLYS on surreal depression.
1 · Reply
CH_Expat
CH_Expat Jun. 16 at 4:25 PM
$CRNX The brimstone butterfly is called "Zitronenfalter" (direct translation: lemon folderer) in German. There is saying when something absurd is happening: If you believe this, you also believe the "Zitronenfalter" is folding lemons. Price action of this stock made me go for this posting.
0 · Reply
CH_Expat
CH_Expat Jun. 15 at 7:58 PM
$CRNX Excellent data at ENDO congress worth an epic 1% up green day.
0 · Reply